Neuromuscular Agents

"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

Descriptor ID	D009465
MeSH Number(s)	D27.505.696.663.700
Concept/Terms	Neuromuscular Agents Neuromuscular Agents Agents, Neuromuscular Skeletal Muscle Relaxants Skeletal Muscle Relaxants Muscle Relaxants, Skeletal Relaxants, Skeletal Muscle Neuromuscular Effect Neuromuscular Effect Effect, Neuromuscular Neuromuscular Effects Effects, Neuromuscular

Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Peripheral Nervous System Agents [D27.505.696.663]
Neuromuscular Agents [D27.505.696.663.700]

Below are MeSH descriptors whose meaning is related to "Neuromuscular Agents".

Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.

Bar chart showing 27 publications over 18 distinct years, with a maximum of 3 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
2000	1	0	1
2002	0	1	1
2003	1	0	1
2004	1	0	1
2005	0	1	1
2006	0	2	2
2008	1	0	1
2009	1	0	1
2010	0	2	2
2011	0	1	1
2012	0	1	1
2013	2	1	3
2016	1	1	2
2018	2	0	2
2019	2	0	2
2020	2	0	2
2024	0	2	2

Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.

Gollomp SM, Khalifian S, Gokhale S. Mitigating Immunogenicity by Coordinating Botulinum Toxin Treatments Between Aesthetics and Therapeutics. Dermatol Surg. 2024 09 01; 50(9S):S35-S37.

View in: PubMed
Heckert K, Biering-S?rensen B, B?umer T, Khan O, Pagan F, Paulin M, Stitik T, Verduzco-Gutierrez M, Reebye R. Delphi Analysis: Optimizing Anatomy Teaching and Ultrasound Training for Botulinum Neurotoxin Type A Injection in Spasticity and Dystonia. Toxins (Basel). 2024 08 21; 16(8).

View in: PubMed
Hjelm N, Crippen M, Azizzadeh B. Long-Term Changes in the Treatment Pattern of Botulinum Toxin A Injections for Postfacial Paralysis Synkinesis Following Modified Selective Neurectomy. Facial Plast Surg Aesthet Med. 2021 May-Jun; 23(3):234-235.

View in: PubMed
Sergott RC, Amorelli GM, Baranello G, Barreau E, Beres S, Kane S, Mercuri E, Orazi L, SantaMaria M, Tremolada G, Santarsiero D, Waskowska A, Yashiro S, Denk N, F?rst-Recktenwald S, Gerber M, Gorni K, Jaber B, Jacobsen B, Mueller L, Nave S, Scalco RS, Marzoli SB. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2021 01; 8(1):54-65.

View in: PubMed
Reichenbach ZW, Stanek S, Patel S, Ward SJ, Malik Z, Parkman HP, Schey R. Botulinum Toxin A Improves Symptoms of Gastroparesis. Dig Dis Sci. 2020 05; 65(5):1396-1404.

View in: PubMed
Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. J Headache Pain. 2019 Feb 01; 20(1):12.

View in: PubMed
Bilyk JR, Yen MT, Bradley EA, Wladis EJ, Mawn LA. Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018 09; 125(9):1459-1467.

View in: PubMed
Greenhill DA, Wissinger K, Trionfo A, Solarz M, Kozin SH, Zlotolow DA. External Rotation Predicts Outcomes After Closed Glenohumeral Joint Reduction With Botulinum Toxin Type A in Brachial Plexus Birth Palsy. J Pediatr Orthop. 2018 Jan; 38(1):32-37.

View in: PubMed
Ahmad J, Ahmad SH, Jones K. Treatment of Plantar Fasciitis With Botulinum Toxin. Foot Ankle Int. 2017 Jan; 38(1):1-7.

View in: PubMed
Hamdy RC, Montpetit K, Aiona MD, MacKenzie WG, van Bosse HJ, Narayanan U, Raney EM, Chafetz RS, Thomas SE, Weir S, Gregory S, Yorgova P, Takahashi S, Rinaldi M, Zhang X, Dahan-Oliel N. Safety and Efficacy of Botulinum Toxin A in Children Undergoing Lower Limb Lengthening and Deformity Correction: Results of a Double-blind, Multicenter, Randomized Controlled Trial. J Pediatr Orthop. 2016 Jan; 36(1):48-55.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement